Journal article · 2026 · Open access

Identifying Pediatric and Developmental Screening Targets With Biologically Informed Molecular Representations

Jose Miguel Acitores Cortina, Martijn C. Schut, Nicholas P. Tatonetti

Clinical Pharmacology & Therapeutics · Published 13 November 2026 · DOI 10.1002/cpt.70555

Open PDFView at the publisherCite this paper

In brief

“Identifying Pediatric and Developmental Screening Targets With Biologically Informed Molecular Representations” is a 2026 journal article by Jose Miguel Acitores Cortina and 2 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 0 citations as of 18 November 2026. It is open access: the full text is free to read at Clinical Pharmacology & Therapeutics.

Citations
0
References
34
Authors
3

Abstract

More than 75% of Food and Drug Administration approved drugs lack pediatric dosing, efficacy, or safety data, and roughly 40% of medications prescribed to children are used off-label. For most therapies children receive, dose, formulation, or indication has never been formally evaluated in anyone under 18. In this work, we build on our previous model, BioMADE, to identify toxicity screening targets whose relevance is specific to defined developmental stages. We analyzed 3.8 million drug-condition records from KidSIDES across 7 developmental stages and 6 system organ classes. Univariate analysis identified biologically coherent genes associated with pediatric conditions, including known genes like GABRB1 (pathogenic variants cause developmental and epileptic encephalopathy), SLC6A1 (associated with developmental encephalopathies), and GRIN2A (defining gene of epilepsy-aphasia spectrum). Signals were the strongest in early life, spanning multiple organ systems. The highest univariate model was gene CTSS, area under the receiver operating characteristic curve of 0.776; 95% confidence interval 0.62-0.90. Multivariate models surpassed 0.8 area under receiving operator curve in 13 datasets (0.81-0.91), indicating that multi-gene drug interaction profiles carry predictive signal beyond single-target associations. We further identify secondary targets that may influence pediatric development and contribute to pediatric-specific adverse drug events, many of which are not included in current safety screening panels. Our findings support the development of novel pediatric-specific safety screening panels, with a particular emphasis on respiratory and congenital disorders in early life. Prioritizing relevant drug targets for pediatric screening can potentially reduce the challenges of pediatric clinical trials and advance safer, more precise pediatric drug therapies.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Cortina, J. M. A., Schut, M. C., & Tatonetti, N. P. (2026). Identifying Pediatric and Developmental Screening Targets With Biologically Informed Molecular Representations. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70555

MLA 9

Cortina, Jose Miguel Acitores, et al. “Identifying Pediatric and Developmental Screening Targets With Biologically Informed Molecular Representations.” Clinical Pharmacology & Therapeutics, 2026. https://doi.org/10.1002/cpt.70555.

Chicago

Cortina, Jose Miguel Acitores, Martijn C. Schut, and Nicholas P. Tatonetti. 2026. “Identifying Pediatric and Developmental Screening Targets With Biologically Informed Molecular Representations.” Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70555.

Harvard

Cortina, J. M. A., Schut, M. C. and Tatonetti, N. P. (2026) ‘Identifying Pediatric and Developmental Screening Targets With Biologically Informed Molecular Representations’, Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.70555.

IEEE

J. M. A. Cortina, M. C. Schut, and N. P. Tatonetti, “Identifying Pediatric and Developmental Screening Targets With Biologically Informed Molecular Representations,” Clinical Pharmacology & Therapeutics, 2026, doi: 10.1002/cpt.70555.

BibTeX

@article{cortina2026identifying,
  title     = {{Identifying Pediatric and Developmental Screening Targets With Biologically Informed Molecular Representations}},
  author    = {Cortina, Jose Miguel Acitores and Schut, Martijn C. and Tatonetti, Nicholas P.},
  journal   = {Clinical Pharmacology \& Therapeutics},
  year      = {2026},
  doi       = {10.1002/cpt.70555},
  url       = {https://doi.org/10.1002/cpt.70555}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices

  • drug safety in children
  • developmental toxicity screening
  • developmental stages
  • GABRB1
  • SLC6A1
  • GRIN2A
  • cathepsin S
  • adverse drug reactions

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Cortina, J. M. A., Schut, M. C., & Tatonetti, N. P. (2026). Identifying Pediatric and Developmental Screening Targets With Biologically Informed Molecular Representations. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70555

How many times has this paper been cited?

0 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.

Who wrote this paper?

Jose Miguel Acitores Cortina, Martijn C. Schut, Nicholas P. Tatonetti.

What is the DOI of this paper?

10.1002/cpt.70555, permanently at https://doi.org/10.1002/cpt.70555. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.